The rise of bispecific T-cell engager (BsTCE) antibodies: a potentially game-changing approach for breast cancer therapy? [0.03%]
双特异T细胞接头(BsTCE)抗体在乳腺癌治疗中的崛起——一场变革性的革命？
Pravin U Gudavalekar,Prakash Y Khandave,Suchita Shalini et al.
Pravin U Gudavalekar et al.
Over the past decade, there has been exponential growth in the development of bispecific T-cell engager (BsTCE) antibodies, along with their immunotherapeutic applications in oncology. BsTCEs are an emerging class of bispecific antibodies t...
Artificial intelligence revolutionizing CNS drug discovery and development [0.03%]
人工智能助力中枢神经系统药物研发转型升级
Md E K Talukder,Mohammad Rashedul Islam,Saghir Ali et al.
Md E K Talukder et al.
Central nervous system (CNS) drug discovery faces high attrition rates, long timelines and substantial costs due to complex disease biology and the difficulties in safe drug delivery. Conventional CNS processes remain slow and trial-and-err...
Upendra Nayek,Tusha Sharma,Vivek K Kashyap et al.
Upendra Nayek et al.
Hepatopancreatobiliary (HPB) cancers remain among the most aggressive malignancies. Nanobodies are single-domain antibodies derived from camelid heavy-chain-only immunoglobulins. They offer distinct advantages, including small size, stabili...
Multidisciplinary review method for novel target identification and prioritization for neurodegenerative diseases [0.03%]
用于神经退行性疾病新靶点识别和选择的多学科审评方法学
Tatiana Rosado Rosenstock,Hiromitsu Ohzeki,Shohei Kumagai et al.
Tatiana Rosado Rosenstock et al.
Target identification (Target ID) is a foundational, multi-disciplinary method for identifying novel therapeutic targets in drug discovery, including in complex neurodegenerative diseases. Here, we outline a collaborative approach to identi...
Strategic adoption of model-informed drug development (MIDD) as an overarching business model in biotechnology and life science industry [0.03%]
基于模型的药物开发在生物技术和生命科学产业中的战略采纳及商业模式构建
Rajesh Krishna
Rajesh Krishna
Model-informed drug development (MIDD) has matured from a cottage craft into a system of evidence that connects discovery, development, registration, labeling, and even post-approval clinical practice. The international regulatory architect...
Cognition-enhancing drugs: current landscape, mechanisms, and future prospects [0.03%]
认知增强药物：现状、机制和未来前景
Mengyuan Zhang,Cong Lin,Weidong Zhang et al.
Mengyuan Zhang et al.
Cognition-enhancing drugs (CEDs) are pharmacological agents aimed at improving memory, attention, and executive function. This review explores both established and emerging CEDs that target neurotransmitter systems, neuroinflammation, and n...
Sodium taurocholate cotransporting polypeptide in HBV-related diseases: from underlying mechanisms to targeted therapies [0.03%]
牛磺胆酸钠共转运多肽在乙型肝炎病毒感染相关性疾病中的作用：从发病机制到靶向治疗
Qiang Xie,Qingbo Liu,Xin Zheng et al.
Qiang Xie et al.
Hepatitis B virus (HBV) remains a leading cause of liver fibrosis and hepatocellular carcinoma, posing a major global health burden. Current therapies, including interferons and nucleotide analogs, have limited curative efficacy. The identi...
Addressing delivery and resistance issues of CDK4/6 inhibitors as cancer therapeutics [0.03%]
克服CDK4/6抑制剂作为抗癌药物的递送和耐药性问题
Kshitiz Luthra,Nalla Usha Kumari,Sri Pada Datta Chigurupati et al.
Kshitiz Luthra et al.
Cancer treatment is limited by poor specificity, efficacy, toxicity and resistance associated with conventional treatment options involving surgery, chemotherapy, and radiation therapy. The introduction of newer targeted agents, such as cyc...
Implementing drug data exclusivity in China: A comparative analysis with global practices [0.03%]
中国药品数据保护的落地实施——全球实践对比分析研究
Yu Chen,Xufeng Lv,Yun Li et al.
Yu Chen et al.
This article provides a comprehensive overview and comparative analysis of China's forthcoming drug data exclusivity system, contextualizing it within global frameworks. It presents the current data exclusivity regimes of the United States,...
Protein exosites as drug targets: from structural topology to therapeutic modality [0.03%]
蛋白质exo位点作为药物靶标：从结构拓扑到治疗方式
Folorunsho Bright Omage,Ivan Mazoni,Inácio Henrique Yano et al.
Folorunsho Bright Omage et al.
Bivalirudin's FDA approval (2000) validated bivalent thrombin inhibition via simultaneous engagement of the catalytic site and exosite I as a route to selective anticoagulants. Yet clinical translation of exosite targeting has largely remai...